Pharmacology, Toxicology and Pharmaceutical Science
Phase I Trials
100%
Doxorubicin
73%
Phase II Trials
66%
Cyclophosphamide
66%
Tipifarnib
66%
Breast Cancer
66%
Docetaxel
66%
Disease
42%
Metastatic Breast Cancer
38%
Pancreas Cancer
33%
Gemcitabine
33%
Etoposide
33%
Capecitabine
33%
Clinical Trial
33%
Irinotecan
33%
SARS Coronavirus
33%
Monoclonal Antibody
33%
Trastuzumab
33%
Adenocarcinoma
33%
Nonhodgkin Lymphoma
33%
Idarubicin
33%
Carcinoma
33%
Granulocyte Colony Stimulating Factor
31%
Neutropenia
27%
Coronavirinae
16%
STAT3 Protein
14%
Overall Survival
13%
Thrombocytopenia
13%
Failure Free Survival
13%
Taxane
12%
Hand Foot Syndrome
9%
Maximum Tolerated Dose
9%
Primary Tumor
9%
Protein Farnesyltransferase Inhibitor
9%
Febrile Neutropenia
7%
Infection
6%
Neoplasm
6%
Hypotension
6%
Infectious Complication
6%
Mucosa Inflammation
6%
Nausea
6%
Anemia
6%
Dyspnea
6%
Leukopenia
6%
Keyphrases
Capecitabine
61%
Advanced Carcinoma
33%
Chemotherapy
33%
Gastrointestinal
33%
Phase I Clinical Trial
33%
Pancreatic Cancer Screening
33%
Advanced Breast Cancer
33%
Lymphoma
33%
Nursing Support
33%
Continuous Intravenous Infusion
33%
Dose-dense
33%
Tipifarnib
33%
Irinotecan
33%
Phase I Trial
33%
Solid Malignancies
33%
Ixabepilone
33%
Gemcitabine
33%
Neutropenia
20%
Dose Level
18%
Severe Acute Respiratory Syndrome Coronavirus 2 Variants
16%
Locally Advanced Breast Cancer
16%
Adverse Events
16%
Taxanes
16%
Anthracyclines
16%
Nurse Experience
16%
Farnesyltransferase
14%
Intermediate Grade
13%
Mucositis
12%
Dose-limiting Toxicity
9%
Maximum Tolerated
9%
Hand-foot Syndrome
9%
Plasma Donation
8%
Positive Work Environment
8%
On-the-job Training
8%
Black-serving Hospitals
8%
2-cycles
6%
Toxicity Profile
6%
Preclinical Data
6%
Hypotension
6%
Relapsed Disease
6%
Thrombocytopenia
6%
Prolonged Infusion
6%
Recommended Phase 2 Dose
6%
Nausea-vomiting
6%
Tumor Subtype
6%
High Toxicity
6%
Dyspnea
6%
Fever
6%
Peripheral Neuropathy
5%
Nausea
5%
Medicine and Dentistry
COVID-19
50%
Infusion
33%
Monoclonal Antibody
33%
Severe Acute Respiratory Syndrome Coronavirus 2
33%
Endoscopic Ultrasound
33%
Pancreas Cancer
33%
Locally Advanced Breast Cancer
33%
Gemcitabine
33%
Tipifarnib
33%
Magnetic Resonance Imaging
33%
Dose Densification
33%
Cancer Screening
33%
Intravenous Drug Administration
33%
Phase I Trials
33%
Carcinoma
33%
Interprofessional Education
33%
Health Care
16%
Health Outcomes
8%
Work Environment
8%
Neutropenia
6%
Nausea
6%
Neoplasm
6%
Mucositis
6%
Thrombocytopenia
6%
Hypotension
6%
Dyspnea
6%
Pancreatic Duct
5%
Family History
5%
Adenocarcinoma
5%
Screening
5%
